Literature DB >> 24990994

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Muriel Lavie1, Stéphane Sarrazin2, Roland Montserret2, Véronique Descamps3, Thomas F Baumert4, Gilles Duverlie3, Karin Séron1, François Penin2, Jean Dubuisson5.   

Abstract

UNLABELLED: In spite of the high variability of its sequence, hepatitis C virus (HCV) envelope glycoprotein E2 contains several conserved regions. In this study, we explored the structural and functional features of the highly conserved E2 segment from amino acid (aa) 502 to 520, which had been proposed as a fusion peptide and shown to strongly overlap a potential conserved neutralizing epitope. For this purpose, we used reverse genetics to introduce point mutations within this region, and we characterized the phenotypes of these mutants in the light of the recently published structure of E2. The functional analyses showed that their phenotypes are in agreement with the positions of the corresponding residues in the E2 crystal structure. In contrast, our data ruled out the involvement of this region in membrane fusion, and they indicate that alternative conformations would be necessary to expose the potential neutralizing epitope present in this segment. Of particular interest, we identified three specific mutations (Y507L, V514A, and V515A) located within this neutralizing epitope which only mildly reduced infectivity and showed no assembly defect. These mutations modulated HCV dependence on the viral receptor SRB1, and/or they also modulated virion sensitivity to neutralizing antibodies. Importantly, their characterization also showed that amino acids Y507, V514, and V515 contribute to E2 interaction with HCV receptor CD81. In conclusion, our data show that the highly conserved E2 segment from aa 502 to 520 plays a key role in cell entry by influencing the association of the viral particle with coreceptors and neutralizing antibodies. IMPORTANCE: Hepatitis C virus (HCV) envelope proteins E1 and E2 exhibit sequence variability. However, some segments of the envelope proteins are highly conserved, suggesting that these sequences play a key role at some steps of the HCV life cycle. In this work, we characterized the function and structure of a highly conserved E2 region that is targeted by neutralizing antibodies and had been proposed as a fusion peptide. Our data ruled out the involvement of this region in membrane fusion but allowed for the identification of new residues modulating the interaction of the virus with entry factors and its sensitivity to neutralizing antibodies. Moreover, structural data suggest that alternative conformations could exist for E2, which would explain the presence of a partially masked neutralizing epitope in this segment in the currently available E2 structure. Overall, our findings highlight the importance of conserved regions in the sequences of HCV envelope proteins.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990994      PMCID: PMC4178871          DOI: 10.1128/JVI.01402-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Hepatitis C databases, principles and utility to researchers.

Authors:  Carla Kuiken; Masashi Mizokami; Gilbert Deleage; Karina Yusim; Francois Penin; Tadasu Shin-I; Céline Charavay; Ning Tao; Daniel Crisan; Delphine Grando; Anita Dalwani; Christophe Geourjon; Ashish Agrawal; Christophe Combet
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

2.  The membrane-active regions of the hepatitis C virus E1 and E2 envelope glycoproteins.

Authors:  Ana J Pérez-Berna; Miguel R Moreno; Jaime Guillén; Angela Bernabeu; José Villalaín
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

3.  Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.

Authors:  David Delgrange; André Pillez; Sandrine Castelain; Laurence Cocquerel; Yves Rouillé; Jean Dubuisson; Takaji Wakita; Gilles Duverlie; Czeslaw Wychowski
Journal:  J Gen Virol       Date:  2007-09       Impact factor: 3.891

Review 4.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Authors:  Peter Simmonds; Jens Bukh; Christophe Combet; Gilbert Deléage; Nobuyuki Enomoto; Stephen Feinstone; Phillippe Halfon; Geneviève Inchauspé; Carla Kuiken; Geert Maertens; Masashi Mizokami; Donald G Murphy; Hiroaki Okamoto; Jean-Michel Pawlotsky; François Penin; Erwin Sablon; Tadasu Shin-I; Lieven J Stuyver; Heinz-Jürgen Thiel; Sergei Viazov; Amy J Weiner; Anders Widell
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

5.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

7.  Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus.

Authors:  Dimitri Lavillette; Eve-Isabelle Pécheur; Peggy Donot; Judith Fresquet; Jennifer Molle; Romuald Corbau; Marlène Dreux; François Penin; François-Loïc Cosset
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

8.  The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins.

Authors:  Patrick Maillard; Thierry Huby; Ursula Andréo; Martine Moreau; John Chapman; Agata Budkowska
Journal:  FASEB J       Date:  2006-02-13       Impact factor: 5.191

9.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

10.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.

Authors:  Matthew J Evans; Thomas von Hahn; Donna M Tscherne; Andrew J Syder; Maryline Panis; Benno Wölk; Theodora Hatziioannou; Jane A McKeating; Paul D Bieniasz; Charles M Rice
Journal:  Nature       Date:  2007-02-25       Impact factor: 49.962

View more
  20 in total

1.  Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Authors:  Rehab I Moustafa; Juliano G Haddad; Lydia Linna; Xavier Hanoulle; Véronique Descamps; Ahmed Atef Mesalam; Thomas F Baumert; Gilles Duverlie; Philip Meuleman; Jean Dubuisson; Muriel Lavie
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

2.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Authors:  Brian G Pierce; Zhen-Yong Keck; Patrick Lau; Catherine Fauvelle; Ragul Gowthaman; Thomas F Baumert; Thomas R Fuerst; Roy A Mariuzza; Steven K H Foung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

3.  Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.

Authors:  Jordan J Feld; Marcelo Cypel; Deepali Kumar; Harel Dahari; Rafaela Vanin Pinto Ribeiro; Nikki Marks; Nellie Kamkar; Ilona Bahinskaya; Fernanda Q Onofrio; Mohamed A Zahoor; Orlando Cerrochi; Kathryn Tinckam; S Joseph Kim; Jeffrey Schiff; Trevor W Reichman; Michael McDonald; Carolina Alba; Thomas K Waddell; Gonzalo Sapisochin; Markus Selzner; Shaf Keshavjee; Harry L A Janssen; Bettina E Hansen; Lianne G Singer; Atul Humar
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-06

4.  Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Authors:  Maude Boisvert; Wanrui Zhang; Elizabeth J Elrod; Nicole F Bernard; Jean-Pierre Villeneuve; Julie Bruneau; Joseph Marcotrigiano; Naglaa H Shoukry; Arash Grakoui
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

5.  Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.

Authors:  Soma Das; Ranajoy Mullick; Anuj Kumar; Himani Tandon; Mihika Bose; K Gouthamchandra; Madhavi Chandra; Bagepally Ravishankar; M N Khaja; Narayanaswamy Srinivasan; Saumitra Das; Shaila Melkote Subbarao; Anjali Anoop Karande
Journal:  J Gen Virol       Date:  2017-05-08       Impact factor: 3.891

6.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

Review 7.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

Review 8.  Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy.

Authors:  Daniela Ploen; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

9.  Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2.

Authors:  Aparajita Nayak; Nagarajan Pattabiraman; Numrah Fadra; Radoslav Goldman; Sergei L Kosakovsky Pond; Raja Mazumder
Journal:  J Biomol Struct Dyn       Date:  2014-10-15

10.  Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion.

Authors:  Pierre Falson; Birke Bartosch; Khaled Alsaleh; Birke Andrea Tews; Antoine Loquet; Yann Ciczora; Laura Riva; Cédric Montigny; Claire Montpellier; Gilles Duverlie; Eve-Isabelle Pécheur; Marc le Maire; François-Loïc Cosset; Jean Dubuisson; François Penin
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.